News
FPRX
--
0.00%
--
News On Five Prime Therapeutics Inc. (FPRX) Now Under AMGN
News On Five Prime Therapeutics Inc. (FPRX) Now Under AMGN
Dow Jones · 18h ago
Amgen completes $1.9B acquisition of Five Prime Therapeutics
Amgen (AMGN) announces that it has completed its previously announced tender offer to purchase all outstanding shares of Five Prime Therapeutics (FPRX) in a deal valued at ~$1.9B."Five Prime fits
Seekingalpha · 1d ago
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
, /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology comp...
PR Newswire - PRF · 1d ago
Press Release: Amgen Successfully Completes -2-
Dow Jones · 1d ago
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics >AMGN FPRX
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics >AMGN FPRX
Dow Jones · 1d ago
8-K: FIVE PRIME THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- 2021-04-15 false 0001175505 0001175505 2021-04-15 2021-04-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C....
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
BRIEF-Five Prime Says U.S. FDA Approved Co's Request For Breakthrough Therapy Designation For Bemarituzumab
reuters.com · 1d ago
Axitinib Market Size, Share, Trend 2021, Industry Overview, Outlook, Trends Evaluation, Geographical Segmentation, Business Challenges and Opportunity Analysis till 2026
Apr 15, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The “Axitinib Market” Research Report...
The Express Wire · 2d ago
Cancer Angiogenesis Inhibitors Market Research Report by Type, by Product, by Application - Global Forecast to 2027 - Cumulative Impact of COVID-19
Apr 06, 2021 (Market Stats News via COMTEX) -- A new market research report titled "Global Cancer Angiogenesis Inhibitors Market 2021 Analysis and Industry...
Market Stats News · 04/06 21:10
Global Cytotoxic T Lymphocyte Protein 4 Market Trend Survey 2021-2027 with Top Countries Data: Industry Insights by Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen | With Covid-19 Analysis
Apr 05, 2021 (The Expresswire) -- Global “Cytotoxic T Lymphocyte Protein 4 Market” research report (2021-2027) covers the market outline and topographical...
The Express Wire · 04/05 05:03
Cytotoxic T Lymphocyte Protein 4 Market Growth, Share, Trends and Forecasts 2020 to 2027 By Ameco Research
pune, India, Thu, 25 Mar 2021 02:14:30 / Comserve Inc. / -- The global Cytotoxic T Lymphocyte Protein 4 market is segmented by company, region (country), by...
Comserve · 03/25 06:16
Best Stocks To Invest In Right Now? 4 Biotech Stocks To Know
Mar 24, 2021 (StockMarket.com via COMTEX) -- Top Biotech Stocks To Watch In The Stock Market Today Biotech stocks remain on many investors' radar and for...
StockMarket.com · 03/24 22:00
Five Prime's Revival a Lesson for Biotech Investors
GuruFocus News · 03/24 17:39
Prime Time's Revival a Lesson for Biotech Investors
GuruFocus News · 03/24 17:39
Axitinib Market Size, Share & Trends Analysis Report by Type, by Application, by End Use and Segment Forecasts 2026 || Sanofi, Acceleron Pharma, Five Prime Therapeutics, Allergan
Mar 24, 2021 (Market Insight Reports) -- Global Axitinib Market Research Report 2020-2026 shares a versatile overview of the market scenario including the...
Market Insight Reports · 03/24 06:03
Cancer Angiogenesis Inhibitors Market Brief Analysis By top Leading Companies from 2020-2027 | Ameco Research
Comserve · 03/23 07:55
T Cell Specific Surface Glycoprotein CD28 Market Analysis, Growth Trends and Key Competitive Assessment through 2027 |Ameco Research
pune, India, Tue, 23 Mar 2021 03:37:01 / Comserve Inc. / -- T Cell Specific Surface Glycoprotein CD28 Market (2020) Report provides Market Analysis on the...
Comserve · 03/23 07:38
10-K: FIVE PRIME THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/22 10:13
DJ Benefitfocus and Five Prime Therapeutics See Analyst Action -- Barrons.com
Dow Jones · 03/19 23:49
Though Potential Bidders Moved Away, Amgen's Bid For Five Prime Outlasted 15 Suitors
Earlier this month, biotech giant Amgen Inc (NASDAQ: AMGN) 
Benzinga · 03/19 18:29
Webull provides a variety of real-time FPRX stock news. You can receive the latest news about Five Prime through multiple platforms. This information may help you make smarter investment decisions.
About FPRX
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company’s pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.